A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
Part of paid clinical trials in Concord, California.
- Sponsor
- Lexicon Pharmaceuticals
- Study ID
- NCT02531035
- Phase
- PHASE3
- Status
- Completed
Conditions
- High Level of Sugar (Glucose) in the Blood
- Type 1 Diabetes Mellitus (T1DM)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Sotagliflozin — DRUGSotagliflozin, once daily, before the first meal of the day
- Placebo — DRUGPlacebo, once daily, before the first meal of the day
Study Details
This Phase 3 study was designed to demonstrate the net benefit of sotagliflozin versus placebo in patients with Type 1 Diabetes (T1D).
Key Dates
- Start date
- Sep 30, 2015
- Status verified
- Feb 2020
- Primary completion
- Apr 30, 2017
- Completion
- Apr 30, 2017
Study Design
- Enrollment
- 1,405 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: PlaceboTwo placebo-matching to sotagliflozin tablets daily, orally, before the first meal of the day for 24 weeks.
- Experimental: Sotagliflozin 400 mgSotagliflozin 400 milligram (mg) (two 200 mg tablets) once daily, orally, before the first meal of the day for 24 weeks.
Primary Outcome Measure
Percentage of Participants With A1C <7.0% at Week 24 and No Episode of Severe Hypoglycemia and No Episode of Diabetic Ketoacidosis (DKA) After Randomization [ Time Frame: Week 24 ]
Locations (33)
Find similar trials in Concord, CA
Related Studies
- Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage ExerciseNot Yet Recruiting · Stanford University · Palo Alto, California
- Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital DischargeRecruiting · Vanderbilt University Medical Center · Nashville, Tennessee